Dr. Azad on the Design of the ARCHES Trial in mHSPC

Arun Azad, PhD, an associate professor at Peter MacCallum Cancer Centre and the University of Melbourne; fellow at Victorian Cancer Agency; and chair of the ANZUP Cancer Trials Group Translational, discusses the design of the ​phase 3ARCHES trial in metastatic hormone-sensitive prostate cancer (mHSPC).

​The ARCHES study randomized patients with mHSPC to receive androgen deprivation therapy with enzalutamide (Xtandi) or placebo.

The trial was designed to evaluate ​all men with mHSPC ​rather than evaluating 1 specific subtype, says Azad.

Notably, the study included men with low​- and high​-volume mHSPC, ​men with newly diagnosed and relapsed​/refractory ​mHSPC, and ​men who previously received docetaxel.

Additionally, ARCHES was a multicenter, international study​; thus, the data are widely applicable, Azad concludes.